MA43709A - Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations - Google Patents
Composition pharmaceutique comprenant de l'empagliflozine et ses utilisationsInfo
- Publication number
- MA43709A MA43709A MA043709A MA43709A MA43709A MA 43709 A MA43709 A MA 43709A MA 043709 A MA043709 A MA 043709A MA 43709 A MA43709 A MA 43709A MA 43709 A MA43709 A MA 43709A
- Authority
- MA
- Morocco
- Prior art keywords
- empagliflozin
- pharmaceutical composition
- composition consisting
- pharmaceutical
- composition
- Prior art date
Links
- OBWASQILIWPZMG-QZMOQZSNSA-N empagliflozin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=CC=C(Cl)C(CC=2C=CC(O[C@@H]3COCC3)=CC=2)=C1 OBWASQILIWPZMG-QZMOQZSNSA-N 0.000 title 1
- 229960003345 empagliflozin Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662309008P | 2016-03-16 | 2016-03-16 | |
| US201662420062P | 2016-11-10 | 2016-11-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43709A true MA43709A (fr) | 2018-11-28 |
Family
ID=58267120
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043709A MA43709A (fr) | 2016-03-16 | 2017-03-13 | Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations |
Country Status (13)
| Country | Link |
|---|---|
| US (5) | US20170266152A1 (fr) |
| EP (1) | EP3429595A1 (fr) |
| JP (4) | JP7161405B2 (fr) |
| KR (5) | KR20230111262A (fr) |
| CN (3) | CN118286238A (fr) |
| AU (3) | AU2017233889B2 (fr) |
| BR (1) | BR112018016001A2 (fr) |
| CA (1) | CA3017992A1 (fr) |
| CL (1) | CL2018002532A1 (fr) |
| MA (1) | MA43709A (fr) |
| MX (4) | MX2018011088A (fr) |
| PH (1) | PH12018501969A1 (fr) |
| WO (1) | WO2017157816A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7772191B2 (en) | 2005-05-10 | 2010-08-10 | Boehringer Ingelheim International Gmbh | Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein |
| US10610489B2 (en) | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
| UY33937A (es) | 2011-03-07 | 2012-09-28 | Boehringer Ingelheim Int | Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina |
| US11813275B2 (en) | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| PT2981271T (pt) | 2013-04-05 | 2019-02-19 | Boehringer Ingelheim Int | Utilizações terapêuticas de empagliflozina |
| US20140303097A1 (en) | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2014170383A1 (fr) | 2013-04-18 | 2014-10-23 | Boehringer Ingelheim International Gmbh | Composition pharmaceutique, procédés de traitement et leurs utilisations |
| WO2019069230A1 (fr) * | 2017-10-02 | 2019-04-11 | Poxel | Méthodes de traitement d'une insuffisance cardiaque avec fraction d'éjection préservée |
| AU2019282727A1 (en) | 2018-06-06 | 2020-11-26 | Metavant Sciences Gmbh | Methods of treating subjects having diabetes with chronic kidney disease |
| WO2019238647A1 (fr) | 2018-06-14 | 2019-12-19 | Poxel | Comprimé pelliculé comprenant un dérivé de triazine destiné à être utilisé dans le traitement du diabète |
| EP3823631A1 (fr) | 2018-07-19 | 2021-05-26 | Astrazeneca AB | Méthodes de traitement de hfpef au moyen de dapagliflozine et compositions comprenant celle-ci |
| WO2020039394A1 (fr) | 2018-08-24 | 2020-02-27 | Novartis Ag | Nouvelles combinaisons de médicaments |
| CN109846898A (zh) * | 2019-02-01 | 2019-06-07 | 同济大学 | 恩格列净在制备治疗和/或预防心肌梗死的药物中的应用 |
| IT201900006624A1 (it) * | 2019-05-08 | 2020-11-08 | Moret Giannino | Combinazione di canrenone e enalapril per uso nella terapia dei pazienti diabetici. |
| EA202191858A1 (ru) * | 2019-06-12 | 2021-11-12 | Фармакосмос Холдинг А/С | Лечение дефицита железа у субъектов с риском нежелательных явлений со стороны сердечно-сосудистой системы и железо для лечения фибрилляции предсердий |
| PE20211267A1 (es) * | 2019-08-30 | 2021-07-19 | Astrazeneca Ab | Metodos de tratamiento de la insuficiencia cardiaca con fraccion de eyeccion reducida con dapagliflozina |
| WO2021049612A1 (fr) * | 2019-09-13 | 2021-03-18 | 国立大学法人富山大学 | Médicament pour améliorer la rétention de fluide dans une insuffisance cardiaque aiguë |
| MX2022010090A (es) | 2020-02-17 | 2022-09-02 | Boehringer Ingelheim Vetmedica Gmbh | Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de enfermedades cardiacas en felinos. |
| MX2024001184A (es) | 2021-07-28 | 2024-02-27 | Boehringer Ingelheim Vetmedica Gmbh | Uso de inhibidores de sglt-2 para la prevencion y/o tratamiento de cardiopatias en mamiferos no humanos, que excluye felinos, en particular, caninos. |
| JP7396579B2 (ja) * | 2022-01-31 | 2023-12-12 | 壽製薬株式会社 | 左室駆出率が保たれた心不全に対する医薬組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA91546C2 (uk) * | 2005-05-03 | 2010-08-10 | Бьорінгер Інгельхайм Інтернаціональ Гмбх | КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ |
| US7723309B2 (en) * | 2005-05-03 | 2010-05-25 | Boehringer Ingelheim International Gmbh | Crystalline forms of 1-chloro-4-(β-D-glucopyranos-1-yl)-2-[4-((R)-tetrahydrofuran-3-yloxy)-benzyl]-benzene, a method for its preparation and the use thereof for preparing medicaments |
| CL2008002427A1 (es) * | 2007-08-16 | 2009-09-11 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2. |
| HUE029381T2 (en) * | 2009-09-30 | 2017-02-28 | Boehringer Ingelheim Int | A method for preparing a crystalline form of 1-chloro-4- (beta-D-glucopyranos-1-yl) -2- [4 - ((S) -tetrahydrofuran-3-yloxy) benzyl] benzene. |
| US20130035298A1 (en) * | 2011-07-08 | 2013-02-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US9192617B2 (en) * | 2012-03-20 | 2015-11-24 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| US11813275B2 (en) * | 2013-04-05 | 2023-11-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| CA2812016A1 (fr) * | 2013-04-05 | 2014-10-05 | Boehringer Ingelheim International Gmbh | Composition pharmaceutique, procedes pour le traitement et utilisations de celle-ci |
| US20140303097A1 (en) * | 2013-04-05 | 2014-10-09 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, methods for treating and uses thereof |
| WO2014170383A1 (fr) * | 2013-04-18 | 2014-10-23 | Boehringer Ingelheim International Gmbh | Composition pharmaceutique, procédés de traitement et leurs utilisations |
-
2017
- 2017-03-13 JP JP2018548341A patent/JP7161405B2/ja active Active
- 2017-03-13 KR KR1020237023405A patent/KR20230111262A/ko not_active Application Discontinuation
- 2017-03-13 CA CA3017992A patent/CA3017992A1/fr active Pending
- 2017-03-13 CN CN202410254338.3A patent/CN118286238A/zh active Pending
- 2017-03-13 KR KR1020237004848A patent/KR20230028565A/ko not_active IP Right Cessation
- 2017-03-13 CN CN201780018512.2A patent/CN109069525A/zh active Pending
- 2017-03-13 EP EP17710524.4A patent/EP3429595A1/fr active Pending
- 2017-03-13 KR KR1020247017944A patent/KR20240095321A/ko unknown
- 2017-03-13 US US15/456,631 patent/US20170266152A1/en not_active Abandoned
- 2017-03-13 KR KR1020187029941A patent/KR20180122004A/ko not_active IP Right Cessation
- 2017-03-13 WO PCT/EP2017/055767 patent/WO2017157816A1/fr active Application Filing
- 2017-03-13 MA MA043709A patent/MA43709A/fr unknown
- 2017-03-13 CN CN202410254246.5A patent/CN118286237A/zh active Pending
- 2017-03-13 MX MX2018011088A patent/MX2018011088A/es unknown
- 2017-03-13 AU AU2017233889A patent/AU2017233889B2/en active Active
- 2017-03-13 BR BR112018016001A patent/BR112018016001A2/pt not_active Application Discontinuation
- 2017-03-13 KR KR1020237004928A patent/KR20230028568A/ko not_active IP Right Cessation
-
2018
- 2018-07-17 US US16/037,052 patent/US20180318251A1/en not_active Abandoned
- 2018-09-05 CL CL2018002532A patent/CL2018002532A1/es unknown
- 2018-09-13 PH PH12018501969A patent/PH12018501969A1/en unknown
- 2018-09-13 MX MX2024005626A patent/MX2024005626A/es unknown
- 2018-09-13 MX MX2022008491A patent/MX2022008491A/es unknown
- 2018-09-13 MX MX2021010329A patent/MX2021010329A/es unknown
-
2019
- 2019-02-26 US US16/285,774 patent/US20190350894A1/en not_active Abandoned
-
2020
- 2020-06-18 US US16/904,709 patent/US20210059974A1/en not_active Abandoned
-
2021
- 2021-08-04 JP JP2021128431A patent/JP7454531B2/ja active Active
-
2022
- 2022-03-16 US US17/696,075 patent/US20220211659A1/en active Pending
- 2022-10-05 AU AU2022246392A patent/AU2022246392B2/en active Active
- 2022-10-14 JP JP2022165221A patent/JP2023001136A/ja active Pending
-
2024
- 2024-03-11 JP JP2024037260A patent/JP2024083347A/ja active Pending
- 2024-08-29 AU AU2024216447A patent/AU2024216447A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43709A (fr) | Composition pharmaceutique comprenant de l'empagliflozine et ses utilisations | |
| MA50753A (fr) | Compositions d'acide nucléique-polypeptide et utilisations de celles-ci | |
| FR24C1023I1 (fr) | Anticorps thérapeutiques et leurs utilisations | |
| MA50144A (fr) | Anticorps anti-peptides bêta-amyloïdes n3pglu et utilisations associées | |
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA46525A (fr) | Anticorps anti-lag-3 et compositions | |
| MA46820A (fr) | Composition pharmaceutique comprenant des constructions d'anticorps bi-spécifiques | |
| MA43308A (fr) | Molécules d'anticorps se liant à april et leurs utilisations | |
| MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA44659A (fr) | Anticorps anti-tim-3 et compositions | |
| MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
| MA47816A (fr) | Composition pharmaceutique comprenant du sélexipag | |
| MA46990A (fr) | Compositions de glp-1 et leurs utilisations | |
| MA47494A (fr) | Nouvelles utilisations d'anticorps anti-sirpg | |
| MA46742A (fr) | Composition pharmaceutique, méthodes de traitement et leurs utilisations | |
| MA44665A (fr) | Des anti-sirpa anticorps nouvelles et leurs utilisations therapeutiques | |
| MA44262A (fr) | Bioconjugués et utilisations de ceux-ci | |
| MA45233A (fr) | Anticorps anti-gitr et leurs utilisations | |
| MA47459A (fr) | Anticorps anti-tryptase, compositions les contenant et leurs utilisations | |
| FR3032353B1 (fr) | Composition pharmaceutique et dispositif pour le traitement de la douleur | |
| MA43361A (fr) | Composition pour le soin et la protection de cultures | |
| MA52644A (fr) | Compositions pharmaceutiques comprenant de l'acide dgla et leur utilisation | |
| MA51147A (fr) | Associations d'anticorps anti-c5 et utilisations associées | |
| MA43556A (fr) | Combinaisons d'un anticorps ox40 et d'un modulateur tlr4 et utilisations de celles-ci | |
| MA40427A (fr) | Composition comprenant des substances naturelles et/ou des extraits |